World's Best Scientists 2026 revealed!
Charles Erlichman

Charles Erlichman

D-Index & Metrics

Medicine

D-Index
82
Citations
22359
World Ranking
16232
National Ranking
8160

Charles Erlichman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Charles Erlichman sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 354 publications — 28th percentile

28% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Charles Erlichman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Charles Erlichman sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 82 D-Index — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Charles Erlichman is affiliated with the Mayo Clinic in the United States and has a research focus in the field of medicine, with a particular emphasis on oncology. Their work spans multiple subfields including oncology, pathology and forensic medicine, molecular biology, epidemiology, and endocrinology, diabetes, and metabolism.

The scientist has contributed to research topics that include colorectal cancer treatments and studies, genetic factors in colorectal cancer, colorectal cancer screening and detection, neuroendocrine tumor research advances, thyroid cancer diagnosis and treatment, salivary gland tumors diagnosis and treatment, and ear and head tumors.

Frequent coauthors collaborating with Charles Erlichman include Jack Fiskum, Julien Taïeb, Greg Yothers, Richard M. Goldberg, and Takayuki Yoshino.

They have published in a variety of scientific journals, among which the most frequent venues are:

  • Journal of Clinical Oncology
  • JNCI Journal of the National Cancer Institute
  • Thyroid
  • Cancer
  • Pancreatology

Representative recent papers by Charles Erlichman include:

  • Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials, 2020, Journal of Clinical Oncology
  • Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database, 2021, JNCI Journal of the National Cancer Institute
  • An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer, 2020, Thyroid
  • Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination, 2020, Pancreatology
  • A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104), 2023, Cancer

Best Publications

  • A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma.

    C Erlichman;S Fine;A Wong;T Elhakim

  • Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer

    Philip A. Philip;Michelle R. Mahoney;Cristine Allmer;James Thomas

  • Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

    Keith C Bible;Vera J Suman;Julian R Molina;Robert C Smallridge

  • Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.

    M J O'Connell;J A Laurie;M Kahn;R J Fitzgibbons

  • A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.

    I F Tannock;N F Boyd;G DeBoer;C Erlichman

  • The Hsp90 chaperone complex as a novel target for cancer therapy

    M. P. Goetz;D. O. Toft;M. M. Ames;Charles Erlichman

  • Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.

    Stephen M. Ansell;Sara A. Hurvitz;Patricia A. Koenig;Betsy R. LaPlant

  • Phase II Study of Erlotinib in Patients With Advanced Biliary Cancer

    Philip A. Philip;Michelle R. Mahoney;Cristine Allmer;James Thomas

  • Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer

    Matthew P. Goetz;David Toft;Joel Reid;Matthew Ames

  • A Phase I Trial of the Farnesyl Transferase Inhibitor SCH66336: Evidence for Biological and Clinical Activity

    Alex A. Adjei;Charles Erlichman;Jenny N. Davis;David L. Cutler

  • Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).

    Brigette B.Y. Ma;Wan Teck Lim;Boon Cher Goh;Edwin P. Hui

  • The HER Tyrosine Kinase Inhibitor CI1033 Enhances Cytotoxicity of 7-Ethyl-10-hydroxycamptothecin and Topotecan by Inhibiting Breast Cancer Resistance Protein-mediated Drug Efflux

    Charles Erlichman;Scott A. Boerner;Christopher G. Hallgren;Rebecca Spieker

  • Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.

    Sam J. Lubner;Michelle R. Mahoney;Jill L. Kolesar;Noelle K. LoConte

  • A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

    Manuel Hidalgo;Jan C. Buckner;Charles Erlichman;Marilyn S. Pollack

  • Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.

    Shaji K. Kumar;Betsy LaPlant;Wee Joo Chng;Jeffrey Zonder

  • Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non–Small-Cell Lung Cancer

    Alex A. Adjei;Ann Mauer;Laura Bruzek;Randolph S. Marks

  • In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.

    Paul Haluska;Joan M. Carboni;David A. Loegering;Francis Y. Lee

  • A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer

    Elisabeth I. Heath;David W. Hillman;Ulka Vaishampayan;Shijie Sheng

  • Phase I Trial of Daily Oral Polyphenon E in Patients With Asymptomatic Rai Stage 0 to II Chronic Lymphocytic Leukemia

    Tait D. Shanafelt;Tim G. Call;Clive S. Zent;Betsy LaPlant

  • Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group

    Winnie Yeo;Hyun C. Chung;Stephen L. Chan;Ling Z. Wang

Frequent Co-Authors

Alex A. Adjei
Alex A. Adjei Cleveland Clinic
Jeff A. Sloan
Jeff A. Sloan Mayo Clinic
Joseph Rubin
Joseph Rubin Mayo Clinic
Matthew P. Goetz
Matthew P. Goetz Mayo Clinic
Richard M. Goldberg
Richard M. Goldberg West Virginia University
Henry C. Pitot
Henry C. Pitot University of Wisconsin–Madison
Vera J. Suman
Vera J. Suman Mayo Clinic
Ross C. Donehower
Ross C. Donehower Johns Hopkins University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare careers beyond a traditional medical degree, there are many flexible options in the USA. If you’re considering nursing but don’t have a nursing background, online direct entry msn programs for non-nurses provide a fast-track pathway to advanced nursing roles.

Some aspiring nurses seek accessible education options. You can explore the easiest nursing schools to get into to find programs with higher acceptance rates and less competitive entry requirements.

For those drawn to the administrative side of healthcare, medical billing and coding is an in-demand career. If cost is a concern, you may wonder, can you get financial aid for medical billing and coding? Many accredited online programs do offer financial assistance.

If entrance exams are a barrier, look for a nursing school that don't require teas and other standardized tests. These schools offer alternative pathways into the nursing profession, making healthcare more accessible for a wider range of students.

Best Scientists Citing Charles Erlichman

Trending Scientists

Recently Published Articles